In preclinical studies, efzofitimod was found to prevent inflammation and fibrosis in multiple animal models of systemic sclerosis and idiopathic pulmonary fibrosis.
Authors of a systematic review evaluated available literature assessing the role of ultrasound and elastography in skin involvement in systemic sclerosis.
Researchers evaluated the association between forced vital capacity decline and hospitalization events in patients with systemic sclerosis-associated interstitial lung disease.
The Scleroderma Foundation recently changed their name to the National Scleroderma Foundation to better inform the organization’s scope and work in the community.
Researchers explored the impact of elicitation of patient preferences in informing design, enrollment, and modifiable aspects of treatment in future randomized controlled trials.